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To the editor:
Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal
RAS mutations
In a recent issue of Blood, Matsuda et al reported 11 children with
juvenile myelomonocytic leukemia (JMML) and clonal NRAS or
KRAS mutations.1 Three patients showed improvement of various
clinical and laboratory features over a 2- to 4-year period without
chemotherapy or hematopoietic stem cell transplantation (HSCT).
The authors correlate the comparatively mild course with a specific
mutation predicting a glycine-to-serine substitution at position 12
in the NRAS or KRAS protein (G12S), and suggest that “no
chemotherapy may be a recommended management” for JMML
patients with NRAS/KRASG12S.
We have some reason to believe that these conclusions are
premature. Available data do not support that RASG12S has
weaker oncogenic activity than substitutions with valine, argi-
nine, or aspartic acid. Interestingly, the authors show that
myeloid progenitor cells from their patients with G12S respond
to granulocyte macrophage–colony stimulating factor (GM-
CSF) in a comparable manner as other mutants (Figure 1B in
Matsuda et al1). Others reported that HRASG12S led to focus
induction in NIH3T3 cultures with a similar potency as substitu-
tions with arginine or aspartic acid.2
We argue that the clinical course observed in the 3 children is
not uncommon in JMML cases with similar hematologic features
and age. The European Working Group of Myelodysplastic Syn-
dromes in Childhood (EWOG-MDS) has previously shown that
platelet count 33 109/L or more and hemoglobin F less than 15%
at diagnosis identifies a prognostically favorable subgroup in
JMML with a 40% to 70% probability of survival at 2 to 4 years
without HSCT.3 The relatively favorable course in the Matsuda
patients is also because all 3 were less than 1 year old at diagnosis.4
It is known that infants with JMML without severe thrombocytope-
nia at diagnosis may experience transient improvement even
without treatment.5
To examine whether RASG12S is overrepresented in JMML patients
with less aggressive disease (defined as survival 3 years without
HSCT), we reviewed the clinical and molecular data of
216 cases collected in the EWOG-MDS registry, excluding patients
Table 1. Clinical characteristics of patients with JMML and clonal RAS mutations surviving long-term without HSCT
Case
number Mutation
Age,
y Sex Liver, cm Spleen, cm WBC, 109/L Mono, 109/L Hb, g/L Plt, 109/L HbF, %
Outcome (time
from diagnosis)
SC047 NRAS c.G35T
(codon 12 Gly 	 Val)
0.1 M 0 7 23.7 5.2 102 54 10 alive without HSCT
(4.5 y)
I 013 NRAS c.G38A
(codon 13 Gly 	 Asp)
1.7 M 2 2 22.2 2.4 103 40 1.3 alive without HSCT
(5.5 y)
D 175 NRAS c.G35C
(codon 12 Gly 	 Ala)
0.7 F 4 7 18.6 1.3 96 75 3.1 alive without HSCT
(8.8 y)
D 028 NRAS c.G35A
(codon 12 Gly 	 Asp)
0.4 M 3 5 57.4 8.0 112 192 8.3 alive without HSCT
(21.5 y)
CZ011 NRAS c.G35A
(codon 12 Gly 	 Asp)
0.5 M 5 2 57.6 11.5 100 162 6.0 dead without HSCT
(3.3 y)
D 278 KRAS c.C181A
(codon 61 Gln 	 Lys)
0.5 M 2 4 62.5 13.1 87 68 n.d. alive with HSCT
(7.0 y), HSCT
given at 3.3 y
from diagnosis
Matsuda 9 NRAS c.G34A
(codon 12 Gly 	 Ser)
0.8 M 4 5 29.4 4.9 105 113 0.5 alive without HSCT
(4.2 y)
Matsuda 10 NRAS c.G34A
(codon 12 Gly 	 Ser)
0.8 M 5 10 31.8 6.4 54 100 1.7 alive without HSCT
(3.5 y)
Matsuda 11 KRAS c.G34A
(codon 12 Gly 	 Ser)
0.3 F 4 1 21.2 1.7 110 52 8.8 alive without HSCT
(2.5 y)
Liver and spleen sizes are given in cm below the costal margin. Leukemic clones in all patients had a normal karyotype.
WBC indicates white blood cell count; Mono, monocytes; Plt, platelet count; Hb F, fetal hemoglobin; and nd, not done.
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with Noonan syndrome. Fifty patients were not given HSCT within the
first 3 years from diagnosis. Of these, 17 survived this period. Six of
17 carried a clonal RAS mutation (Table 1). It is evident that there
is no appreciable difference in clinical features between the
3 patients reported by Matsuda (included in Table 1 for convenience)
and our 6 patients. However, all 6 patients in our group had substitutions
other than G12S. Overall, only 1 of 216 children had a G12S mutation.
This patient received early HSCT, so the evaluation of his spontaneous
course is precluded. However, he presented with 60% hemoglobin F,
which is usually associated with an aggressive form of the disorder.
We agree that sporadic patients with JMML enjoy long-term
survival without intervention. However, in the absence of reliable
markers that prospectively identify those rare cases, and in view of
the clear superiority of HSCT over other treatment modalities
(probability of 10-year survival 0.39 vs 0.06 without HSCT),3,6 the
EWOG-MDS recommends prompt HSCT for every patient with
JMML, except children with Noonan syndrome.7 Importantly, the
relapse incidence dramatically increases with age (from 18% in
children 2 years old to 73% in patients 4 years old).6 Although
we are not convinced that NRAS/KRASG12S is a useful marker for
treatment decisions, we thank Matsuda and colleagues for stimulat-
ing this discussion and illustrating the need to continue the search
for accurate prognostic markers in JMML.
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Response:
Evaluation of relationship between the genetic abnormalities and disease phenotype is
required in juvenile myelomonocytic leukemia
In their letter, Flotho et al comment on our recently published paper
on spontaneous improvement of hematologic abnormalities in
patients having juvenile myelomonocytic leukemia (JMML) with
NRAS or KRAS2 glycine to serine (Gly12Ser) mutation.1
Our 3 patients with Gly12Ser mutation in the RAS gene
continue hematologic and clinical improvement despite no
chemotherapy 3 to 5 years after diagnosis. Based on no
significant difference in proliferative response of granulocyte-
macrophage (GM) progenitors to low doses of GM colony-
stimulating factor between the patients with Gly12Ser mutation
and the other RAS mutants, Flotho et al claim that our
dose-response study does not support weaker oncogenic activity
of RAS Gly12Ser compared with the activity of the other
substitutions. However, more importantly there is marked
reduction in numbers of circulating GM progenitors during the
clinical course in patients with the RAS Gly12Ser substitution.
Taken together with substantial decreases in leukocyte counts
and spleen size during a 3- to 5-year follow up, their leukemic
burden appears to become smaller.
The European Working Group of Myelodysplastic Syn-
dromes in Childhood (EWOG-MDS) previously showed that
platelet count 33  109/L or more, hemoglobin F less than 15%,
and age younger than 2 years at diagnosis identify a prognosti-
cally favorable subgroup in 72 JMML patients receiving no
allogeneic hematopoietic stem cell transplantation (HSCT).2
However, their genetic background was unclear. Some of the
subjects enrolled in the study might have inactivation of the NF1
gene or mutations in the NRAS, KRAS2, or PTPN11 genes.
Flotho et al presented that 4 patients with NRAS mutation (codon
12 Gly 	 Val, codon 12 Gly 	 Ala, codon 12 Gly 	 Asp, codon
13 Gly 	 Asp) survive 4.5 to 21.5 years without HSCT.
Coupled with our 3 patients with the RAS Gly12Ser mutation,
JMML patients carrying RAS mutations may be heterogenous
with respect to the hematologic progression.
Flotho et al recommend prompt HSCT for every patient with
JMML, except children with Noonan syndrome, based on the
superiority of HSCT over other treatment modalities. In recent
reports,3,4 approximately 50% of JMML patients who received
such transplants were alive and leukemia-free after 4 to 5 years.
The major cause of treatment failure is high incidence of
leukemia recurrence after HSCT. In the results of the EWOG-
MDS/European Blood and Marrow Transplantation (EBMT)
Group trial,4 age younger than 2 years at diagnosis was
associated with a better probability of event-free survival after
HSCT. Nevertheless, it remains to be determined whether interval
between diagnosis and HSCT influences the outcome. Therefore, we
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